|
1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002.CA Cancer J Clin 2005; 55: 74-108. 2.行政院衛生署民國95年侵襲癌發生率及死亡率統計,p5。 3. Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV. Prevalence of human pappillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87: 796-802. 4. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV .The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 241-242. 5. Zur Hausen H. Roots and perspectives of contemporary papillomavirus research. J Cancer Res Clin Oncol 1996; 122: 3-13. 6. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19. 7. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347: 1645-1651. 8. Klug A, Finch JT. Structure of viruses of the papilloma-polyoma type I. Human wart Virus. J Mol Biol 1965; 11: 403-423. 9. zur Hausen H. Papillomavirus infections- a major cause of human cancers. Biochim Biophys Acta 1996; 1288:F55-F78. 10. Jo H, Kim JW. Implications of HPV infection in uterine cervical cancer. Cancer therapy 2005; 3: 419-434. 11. Flores ER, Allen-Hoffmann BL, Lee D, Sattler CA, Lambert PF. Establishment of the human papillomavirus type16 (HPV-16) life cycle in an immortalized human foreskin keratinocyte cell line. Virology 1999; 262: 344-354. 12. Wilson VG, West M, Woytek K, Rangasamy D. Papillomavirus E1 proteins: form, function, and features. Virus Genes 2002; 24: 275-290. 13. You J, Croyle JL, Nishimura A, Ozato K, Howley PM.Interaction of the bovine papillomavirus E2 protein with Brd4 tethers the viral DNA to host mitotic chromosomes. Cell 2004; 117: 349-360. 14. Andersson S, Safari H, Mints M, Lewensohn-Fuchs I, Gyllensten U, Johansson B. Type distribution, viral load, and integration status of high-risk human papillomaviruses in pre-stages of cervical cancer (CIN). Br J Cancer 2005; 92: 2195-2200. 15. Park TW, Fujiwara H, Wright TC. Molecular biology of cervical cancer and its precursors. Cancer 1995; 76: 1902-1913. 16. Ding DC, Hsu HC, Huang RL, Lai HC, Lin CY, Yu MH, Chu TY. Type-specific distribution of HPV along the full spectrum of cervical carcinogenesis in Taiwan: An indication of viral oncogenic potential. Eur J Obstet Gynecol Reprod Biol 2008;140: 245-251. 17. Finzer P, Aguilar-Lemarroy A, Rosl F. The role of human papillomavirus oncoproteins E6 and E7 in apoptosis. Cancer Lett 2002; 188: 15-24. 18. Choo KB, Pan CC, Han SH. Integration of human papillomavirus type 16 into cellular DNA of cervical carcinoma: preferential deletion of the E2 gene and invariable retention of the long control region and the E6/E7 open reading frames. Virology 1987; 161: 259-261. 19. Fontaine J, Hankins C, Mayrand MH, Lefevre J, Money D, Gagnon S, Rachlis A, Pourreaux K, Ferenczy A, Coutlée F; Canadian Women''s HIV Study Group. High levels of HPV-16 DNA are associated with high-grade cervical lesions in women at risk or infected with HIV. AIDS 2005; 19: 785-794. 20. Ho CM, Chien TY, Huang SH, Lee BH, Chang SF. Integrated human papillomavirus types 52 and 58 are infrequently Found In cervical cancer, and high viral loads predict risk of cervical cancer. Gynecol Oncol 2006; 102: 54-60. 21. Peitsaro P, Johansson B, Syrjanen S. Integrated human Papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique. J Clin Microbiol 2002; 40: 886-891. 22. Hengstermann A, Linares LK, Ciechanover A, Whitaker NJ, Scheffner M. Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells.Proc Natl Acad Sci U S A 2001; 98: 1218-1223. 23. Huibregtse JM, Scheffner M, Howley PM. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18.EMBO J 1991; 10: 4129-4135. 24. Mantovani F, Banks L. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 2001; 20: 7874-7887. 25. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63: 1129-1136. 26. Quint WG, Scholte G, van Doorn LJ, Kleter B, Smits PH, Lindeman J. Comparative analysis of human Papillomavirus infections in cervical scrapes and biopsy specimens by general SPF(10) PCR and HPV genotyping. J Pathol 2001; 194: 51-58. 27. Boyer SN, Wazer DE, Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 1996; 56: 4620-4624. 28. Münger K, Basile JR, Duensing S, Eichten A, Gonzalez SL, Grace M, Zacny VL Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 2001;20:7888-7898. 29. Funk JO, Waga S, Harry JB, Espling E, Stillman B, Galloway DA.Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev 1997; 11: 2090-2100. 30. Scheffner M, Munger K, Byrne JC, Howley PM. The state of the p53 and retinoblastoma genes in hunan cervical carcinoma cell lines. Proc Natl Acad Sci U S A 1991; 88: 5523-5527. 31. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogensis. J Natl Cancer Inst 2000; 92: 690-698. 32. Werness BA, Levine AJ. Howley PM. Association of human papillomavirus type 16 and 18 proteins with p53. Science 1990; 248: 76-79. 33. Androphy EJ, Schiller JT, Lowy DR. Identification of the protein encoded by the E6 transforming gene of bovine papillomavirus. Science 1985; 230: 442-445. 34. Watanabe S, Kanda T, Yodhiike K. Human papillomavirus type 16 transformation of primary human embryonic fibroblast requires expression of open reading frame E6 and E7. J Virol 1989; 63: 965-969. 35. Munger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley PM. Complex formation of human papillomavirus E7 protein with the retinoblastoma tumor suppressor gene product. EMBO J 1989; 8: 4099-4105. 36. Smotkin D, Wettstein FO. Transcription of human papillomavirus type 16 early genes in a cervical cancer and a cancer-derived cell line and identification of the E7 protein. Proc Natl Acad Sci U S A 1986; 83: 4680-4684. 37. Brink AA, Snijders PJ, Meijer CJ. HPV detection methods. Dis Markers 2007; 23: 273-281. 38. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-527. 39. Lai CH, Chao A, Chang CJ, Chao FY, Huang HJ, Hsueh S, Lin CT, Cheng HH, Huang CC, Yang JE, Wu TI, Chou HH, Chang TC. Host and viral factors in relation to clearance of human paillomavirus infection: A cohort study in Taiwan. Int J Cancer 2008; 123: 1685-1692. 40. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2: 342-350. 41. Lai CH, Huang HJ, Hsueh S, Chao A, Lin CT, Huang SL, Chao FY, Qiu JT, Hong JH, Chou HH, Chang TC, Chang CJ. Human papillomavirus genotype in cervical cancer: A population-based study. Int J Cancer 2007; 120: 1999-2006. 42. Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zhang T, Scott DR, Rush BB, Lawler P, Sherman ME, et al. Persistence of type-specific human Papillomavirus infection among cytologically normal women. J Infect Dis 1994; 169: 235-240. 43. Chen CA, Liu CY, Chou HH, Chou CY, Ho CM, Twu NF, Kan YY, Chuang MH, Chu TY, Hsieh CY; Taiwan Cooperative Oncologic Group. The distribution and differential risks of human papillomavirus genotypes in cervical preinvasive lesions: A Taiwan Cooperative Oncologic Group Study. Int J Gynecol Cancer 2006; 16: 1801-1808. 44. Huang S, Afonina I, Miller BA, Bechmann M. Human papillomavirus types 52 and 58 are prevalent in cervical cancers from Chenese Women. Int J Cancer 1997; 70: 408-411. 45. Masumoto N, Fujii T, Ishikawa M, Mukai M, Ono A, Iwata T, Kubushiro K, Nozawa S. Dominant human papillomavirus 16 infection in cervical neoplasia in young Japanese women; study of 881 outpatients. Gynecol Oncol 2004; 94: 509-514. 46. An HJ, Cho NH, Lee SY, Kim IH, Lee C, Kim SJ, Mun MS, Kim SH, Jeong JK.Correlation of cervical carcinoma and precancerous lesions with human papillomavirus (HPV) genotypes detected with the HPV DNA chip microarray method. Cancer 2003; 97: 1672-1680. 47. Smith WL, DeWitt DL, Garavito RM.Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000; 69: 145-182. 48. Harris SG, Padilla J, Koumas L, Ray D, Phipps RP. Prostaglandins as modulators of immunity. Trends Immunol 2002; 23: 144-150. 49. Hla T, Ristimaki A, Appleby S, Barriocanal JG. Cyclooxygenase gene expression in inflammation and angiogenesis. Ann NY Acad Sci 1993; 96: 197-204. 50. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998; 38: 97-120. 51. Inoue H, Yokoyama C, Hara S, Tone Y, Tanabe T. Transcriptional regulation of human prostaglandin endoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells. Involvement of both nuclear factor for interleukin-6 expression site and cAMP response element. J Biol Chem 1995; 270: 24965-24971. 52. Subbaramaiah K, Telang N, Ramonetti JT, Araki R, DeVito B, Weksler BB, Dannenberg AJ. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res1996; 56: 4424-4429. 53. Fang HY, Lin TS, Lin JP, Wu YC, Chow KC, Wang LS. Cyclooxygenase-2 in human non-small cell lung cancer. Eur J Surg Oncol 2003; 29: 171-177. 54. Wang LS, Chow KC, Wu YC. Effects of platelet activating factor, butyrate and interleukin-6 on cyclooxygenase-2 expression in human esophageal cancer cells. Scand J Gastroenterol 2002; 37: 467-475. 55. Kutchera W, Jones DA, Matsunami N, Groden J, McIntyre TM, Zimmerman GA, White RL, Prescott SM. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effects. Proc Natl Acad Sci USA 1996; 93: 4816-4820. 56. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN, Up-regulation of cyclooxygenase 2 Gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183-1188. 57. Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997; 57: 1276-1280. 58. Ryu HS, Chang KH, Yang HW, Kim MS, Kwon HC, Oh KS. High cyclooxygenase-2 expression in stage 1B cervical cancer with lymph node metastasis or parametrial invasion. Gynecol Oncol 2000; 76: 320-325. 59. Parett ML, Harris RE, Joarder FS, Ross MS, Clausen KP, Robertson FM. Cyclooxygenase-2 gene expression in human breast cancer. Int J Oncol 1997; 10: 503-507. 60. Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, Edelstein D, Soslow RA, Koki AT, Woerner BM, Masferrer JL, Dannenberg AJ. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999; 59: 991-994. 61. Tucker ON, Dannenberg AJ, Yang EK, Fahey TJ 3rd. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999; 59: 987-990. 62. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF, Hla T. Overexpression of cyclooxygenase-2 is suYcient to induce tumorigenesis in transgenic mice. J Biol Chem 2001; 276: 18563-18569. 63. Tiano HF, Loftin CD, Akunda J, Lee CA, Spalding J, Sessoms A, Dunson DB, Rogan EG, Morham SG, Smart RC, Langenbach R Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res 2002; 62: 3395-3401. 64.金車人類乳突瘤病毒基因定型點墨使用手冊(EASYCHIP Blot Version 1.5)2008; King Car Yuan Shan Institute, YiLan, Taiwan. 65. 常正義,覃志堅,潘雲等。HPV不同亞型感染與子宮頸病變的關聯。右江民族醫學院學報 2009年第31卷第1期p.11-13。 66. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. Int J Cancer 2007; 121: 621-632 . 67. Ueda M, Hung YC, Chen JT. Infection of human papillomavirus and overexpression of dihydrodiol ehydrogenase in uterine cervical cancer. Gynecol Oncol 2006;102:173-181. 68. Sarian LO, Derchain SF, Yoshida A, Vassallo J, Pignataro F, De Angelo Andrade LA. Expression of cyclooxygenase-2 (COX-2) and Ki67 as related to disease severity and HPV detection in squamous lesions of the cervix. Gynecol Oncol 2006; 102: 537-541. 69. Myers ER, McCrory DC, Subramanian S, McCall N, Nanda K, Datta S, Matchar DB. Setting the target for a better cervical screening test: characteristics of a cost-effective test for cervical neoplasia screening. Obstet Gynecol 2000; 96 : 645-652. 70. Hutchinson ML, Zahniser DJ, Sherman ME, Herrero R, Alfaro M, Bratti MC, Hildesheim A, Lorincz AT, Greenberg MD, Morales J, Schiffman M. Utility of liquid-based cytology for cervical carcinoma screening: results of a population-based study conducted in a region of Costa Rica with a high incidence of cervical carcinoma. Cancer 1999; 87: 48-55. 71. Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato M, Nazeyrollas P, Gabriel R, Quereux C, Birembaut P.Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women, Br J Cancer 2001; 84: 1616-1623. 72. Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, Koutsky LA. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 2002; 288: 1749-1757. 73. Raffle AE, Alden B, Quinn M, Babb PJ, Brett MT. Outcomes of screening to prevent cancer: analysis of cumulative incidence of cervical abnormality and modelling of cases and deaths prevented. BMJ 2003; 326: 901. 74. Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, Mielzynska-Lohnas I, Rush BB, Schiffman M. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: A 10-year cohort analysis. J Natl Cancer Inst 2003; 95: 46-52. 75. Gately S, LiWW. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol 2004; 31: 2-11. 76. Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 2002; 62:625-631. 77. Young JL,Jazaeri AA,Darus CJ,Modesitt SC. Cyclooxygenase-2 in cervical neoplasia: a review. Gynecol Oncol 2008; 109: 140-145.
|